var data={"title":"Clindamycin (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clindamycin (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/387892?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clindamycin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clindamycin (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=clindamycin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Clindamycin (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8007987\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Colitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">\n          <i>Clostridium difficile</i>&ndash;associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of <i>C. difficile</i>.</p>\n        <p style=\"text-indent:-4em;margin-left:4em;\">Because clindamycin therapy has been associated with severe colitis, which may end fatally, reserve it for serious infections for which less toxic antimicrobial agents are inappropriate. Do not use clindamycin in patients with nonbacterial infections, such as most upper respiratory tract infections.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">\n          <i>C. difficile</i> produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of <i>C. difficile</i> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <i>C. difficile</i> may need to be discontinued. Institute appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <i>C. difficile</i>, and surgical evaluation as clinically indicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008032\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cleocin;</li>\n      <li>Cleocin in D5W;</li>\n      <li>Cleocin Phosphate;</li>\n      <li>CLIN Single Use</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008033\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Clindamycin;</li>\n      <li>Auro-Clindamycin;</li>\n      <li>Ava-Clindamycin;</li>\n      <li>Clindamycin Injection;</li>\n      <li>Clindamycin Injection SDZ;</li>\n      <li>Clindamycin Injection, USP;</li>\n      <li>Clindamycin IV Infusion;</li>\n      <li>Clindamycine;</li>\n      <li>Dalacin C;</li>\n      <li>Mylan-Clindamycin;</li>\n      <li>PMS-Clindamycin;</li>\n      <li>Riva-Clindamycin;</li>\n      <li>Teva-Clindamycin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008037\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Lincosamide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008117\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dose:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 150 to 450 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 600 to 2,700 mg daily in 2 to 4 divided doses; up to 4,800 mg IV daily may be used in life-threatening infections (maximum: 600 mg/dose IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax (off-label use) (Hendricks 2014): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Postexposure prophylaxis: Oral: 600 mg every 8 hours for 60 days after exposure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cutaneous, treatment: Oral: 600 mg every 8 hours for 7 to 10 days after naturally acquired infection; 60 days following biological weapon related event</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Systemic, treatment: IV: 900 mg every 8 hours; use in combination with a bactericidal antimicrobial (eg, fluoroquinolone, penicillin G); if meningitis is suspected or cannot be ruled out, use in combination with 2 bactericidal antimicrobials (eg, fluoroquinolone <b>and</b> beta-lactam). Duration of therapy is 2 weeks when meningitis has been excluded; &ge;2 to 3 weeks for possible/confirmed meningitis. Patients exposed to aerosolized spores require prophylaxis to complete an antimicrobial course of 60 days from illness onset.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injectional: IV: 600 mg every 8 hours in combination with ciprofloxacin and other antibiotics (eg, a 5-drug combination) (Hicks 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Babesiosis (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 600 mg every 8 hours for 7 to 10 days with quinine (IDSA [Wormser 2006]; Vannier 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 300 to 600 mg every 6 hours for 7 to 10 days with quinine (IDSA [Wormser 2006]; Vannier 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Relapsing infection may require at least 6 weeks of therapy (Vannier 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial vaginosis (alternative to preferred therapy) (off-label use):</b> Oral: 300 mg twice daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wounds (animal) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 300 mg 3 times daily; in combination with a second- or third-generation cephalosporin, levofloxacin, or sulfamethoxazole and trimethoprim (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 600 mg every 6 to 8 hours; in combination with a second- or third-generation cephalosporin, levofloxacin, or sulfamethoxazole and trimethoprim (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic foot infection, mild to moderate (off-label use):</b> Oral: 300 to 450 mg every 6 to 8 hours (Bader 2008; Lipsky 1990). <b>Note:</b> For moderate infection, use in combination with ciprofloxacin or levofloxacin (limited evidence supporting clindamycin for severe <i>S. aureus</i> infections). Check macrolide sensitivity and consider ordering a &ldquo;D-test&rdquo; before using for MRSA (IDSA [Lipsky 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Group B streptococci (neonatal prophylaxis) (off-label use):</b> IV: 900 mg every 8 hours until delivery (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Impetigo:</b> Oral: 300 to 450 mg 4 times daily for 7 days, depending on response (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria, severe (off-label use):</b> IV: Load: 10 mg/kg followed by 5 mg/kg every 8 hours <i>plus</i> IV quinidine gluconate; switch to oral therapy (clindamycin <i>plus</i> quinine) when able for total clindamycin treatment duration of 7 days. <b>Note:</b> Quinine duration is region specific, consult CDC for current recommendations (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria, uncomplicated treatment (off-label use):</b> Oral: 20 mg/kg/day divided every 8 hours for 7 days <i>plus</i> quinine (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis due to MRSA (off-label use):</b> IV, Oral: 600 mg 3 times daily for a minimum of 8 weeks. <b>Note:</b> Some experts combine with rifampin (IDSA [Liu 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis, native vertebral (off-</b>\n      <b>label dose</b>) (<b>IDSA [Berbari 2015]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Staphylococci (oxacillin-susceptible) (alternative therapy):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 600 to 900 mg every 8 hours for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral<i>: </i>300 to 450 mg four times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cutibacterium acnes </i>(alternative therapy): IV: 600 to 900 mg every 8 hours for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease:</b> IV: 900 mg every 8 hours with gentamicin (conventional or single daily dosing); transition from parenteral to clindamycin 450 mg orally 4 times daily (or oral doxycycline) can usually be initiated after 24 to 48 hours of clinical improvement to complete 14 days of total therapy. <b>Note:</b> If tubo-ovarian abscess is present, oral clindamycin in combination with doxycycline is a preferred regimen to complete 14 days of therapy (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis, group A streptococci (GAS) (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute treatment in penicillin-allergic patients:</i> 300 mg every 8 hours for 10 days (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic carrier treatment:</i> 300 mg every 8 hours for 10 days (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Pneumocystis</i></b> <b>pneumonia (PCP) in HIV-infected patients (alternative to preferred therapy) (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 600 mg every 6 hours or 900 mg every 8 hours with primaquine for 21 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 450 mg every 6 hours or 600 mg every 8 hours with primaquine for 21 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia due to MRSA (off-label use):</b> IV, Oral: 600 mg 3 times daily for 7 to 21 days (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against infective endocarditis (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 600 mg 30 to 60 minutes before procedure with no follow-up dose needed (Wilson 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 600 mg 30 to 60 minutes before procedure. Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications (Wilson 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis in total joint replacement in patients undergoing dental procedures which produce bacteremia (off-label use):</b> <b>Note:</b> In general, patients with prosthetic joint implants do not require prophylactic antibiotics prior to dental procedures. In planning an invasive oral procedure, dental consultation with the patient's orthopedic surgeon may be advised to review the risks of infection (Sollecito 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 600 mg 1 hour prior to procedure (ADA 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 600 mg 1 hour prior to procedure (for patients unable to take oral medication) (ADA 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection (off-label use) (IDSA [Osmon 2013]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic antimicrobial suppression, Staphylococci (oxacillin-susceptible) (alternative to cephalexin or cefadroxil) (off-label use):</i> Oral: 300 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cutibacterium acnes, treatment (alternative to penicillin G or ceftriaxone):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 300 to 450 mg every 6 hours for 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 600 to 900 mg every 8 hours for 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic arthritis due to MRSA (off-label use):</b> IV, Oral: 600 mg 3 times daily for 3 to 4 weeks (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections due to MSSA:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 300 to 450 mg 4 times daily for 7 to 14 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 600 mg every 8 hours for 7 to 14 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections due to MRSA (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 300 to 450 mg 4 times daily for 7 to 14 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 600 mg every 8 hours for 7 to 14 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Complicated infections:</i> IV, Oral: 600 mg 3 times daily for 7 to 14 days (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cellulitis:</i> Oral: 300 to 450 mg 3 times daily for 5 to 10 days (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b> IV: 600 to 900 mg every 8 hours, in combination with cefotaxime or ceftriaxone for empiric therapy of polymicrobial infections <b>or</b> in combination with penicillin IV for the treatment of group A streptococcal or <i>Clostridium</i> species necrotizing infections. May give as monotherapy for MSSA. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Streptococcal skin infections:</b> IV: 600 to 900 mg every 8 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis (off-label use):</b> IV: 900 mg within 60 minutes prior to surgical incision. Doses may be repeated in 6 hours if procedure is lengthy (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Toxic shock syndrome:</b> IV: 900 mg every 8 hours with additional concomitant therapy (Lappin 2009; Wong 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Toxoplasma gondii</i></b> <b>encephalitis in HIV-infected patients (off label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment (alternative to preferred regimen):</i> IV, Oral: 600 mg every 6 hours in combination with pyrimethamine and leucovorin. Continue therapy for at least 6 weeks; longer duration may be required if incomplete response or extensive disease (HHS [OI adult 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic maintenance therapy (alternative to preferred regimen):</i> Oral: 600 mg every 8 hours in combination with pyrimethamine and leucovorin; may discontinue when asymptomatic and CD4 count &gt;200 cells/mm<sup>3</sup> for 6 months in response to ART (HHS [OI adult 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008116\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=clindamycin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Clindamycin (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dose:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: IM, IV: Manufacturer&rsquo;s labeling: 15 to 20 mg/kg/day divided every 6 to 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 8 to 40 mg/kg/day in 3 to 4 divided doses; Manufacturer&rsquo;s labeling: 8 to 20 mg/kg/day (as hydrochloride) or 8 to 25 mg/kg/day (as palmitate) in 3 to 4 divided doses; minimum dose of palmitate: 37.5 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: Manufacturer&rsquo;s labeling: 20 to 40 mg/kg/day or 350 to 450 mg/m<sup>2</sup>/day in 3 to 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial rhinosinusitis (off-label use):</b> Oral: 30 to 40 mg/kg/day divided every 8 hours with concomitant cefixime or cefpodoxime for 10 to 14 days. <b>Note:</b> Recommended in patients with non-type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (Chow 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute otitis media (off-label use): </b>Oral: 30 to 40 mg/kg/day in 3 divided doses for 5 to 10 days. Use with or without concomitant third-generation cephalosporin for failure of initial antibiotic therapy; use with a third-generation cephalosporin is recommended for failure of a second course of antibiotics. Duration depends upon illness severity and patient age: Severe illness or &lt;2 years: 10 days; 2 to 5 years: 7 days; children &ge;6 years: 5 to 7 days (Lieberthal 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax (off-label use) (Bradley 2014): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Postexposure prophylaxis: Oral: 30 mg/kg/day divided every 8 hours for 60 days after exposure (maximum: 900 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cutaneous, treatment: Oral: 30 mg/kg/day divided every 8 hours for 7 to 10 days after naturally acquired infection; up to 60 days following biological weapon related event (maximum: 900 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Systemic, treatment: IV: 40 mg/kg/day divided every 8 hours for &ge;14 days (maximum: 900 mg/dose); use in combination with a bactericidal antimicrobial (eg, fluoroquinolone, penicillin G); if meningitis is suspected or cannot be ruled out, use in combination with 2 bactericidal antimicrobials (eg, fluoroquinolone <b>and</b> beta-lactam or glycopeptide). Continue with prophylaxis therapy for up to 60 days from onset of illness.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Babesiosis (off-label use):</b> Oral: 20 to 40 mg/kg/day divided every 8 hours for 7 to 10 days <i>plus</i> quinine (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Impetigo:</b> Oral: 20 mg/kg/day divided every 8 hours for 7 days, depending on response (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria, severe (off-label use):</b> IV: Load: 10 mg/kg followed by 15 mg/kg/day  divided every 8 hours <i>plus</i> IV quinidine gluconate; switch to oral therapy (clindamycin <i>plus</i> quinine) when able for total clindamycin treatment duration of 7 days (<b>Note:</b> Quinine duration is region specific, consult CDC for current recommendations) (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria, uncomplicated treatment (off-label use):</b> Oral: 20 mg/kg/day divided every 8 hours for 7 days <i>plus</i> quinine (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis due to MRSA (off-label use):</b>  IV, Oral: 10 to 13 mg/kg/dose every 6 to 8 hours for a minimum of 4 to 6 weeks (maximum: 40 mg/kg/day) (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis, group A streptococci (IDSA recommendations):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute treatment in penicillin-allergic patients:</i> 21 mg/kg/day divided every 8 hours (maximum: 300 mg per dose) for 10 days (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic carrier treatment:</i> 20 to 30 mg/kg/day divided every 8 hours (maximum: 300 mg per dose) for 10 days (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumocystis pneumonia (PCP) in HIV-infected patients (alternative to preferred therapy) (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Community-acquired pneumonia (CAP) (IDSA/PIDS [Bradley 2011]): Infants &gt;3 months and Children: <b>Note:</b> In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Group A <i>Streptococcus:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe infection (alternative to ampicillin/penicillin): IV: 40 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild infection, step-down therapy (alternative to amoxicillin/penicillin): Oral: 40 mg/kg/day divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Presumed bacterial (in addition to recommended antibiotic therapy), <i>S. pneumoniae</i> moderate to severe (MICs to penicillin &le;2.0 mcg/mL) (alternative to ampicillin/penicillin): IV: 40 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. pneumoniae:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe infection (MICs to penicillin &ge;4.0 mcg/mL) (alternative to ceftriaxone): IV: 40 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild infection, step-down therapy (MICs to penicillin &ge;4.0 mcg/mL) (alternative to levofloxacin or linezolid): Oral: 30 to 40 mg/kg/day divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus</i> (methicillin-susceptible):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe infection (alternative to cefazolin or oxacillin): IV: 40 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild infection, step-down therapy (alternative to cephalexin): Oral: 30 to 40 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus</i> (methicillin-resistant/clindamycin-susceptible):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe infection (preferred): IV: 40 mg/kg/day divided every 6 to 8 hours; recommended duration: 7 to 21 days (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild infection, step-down therapy (preferred): Oral: 30 to 40 mg/kg/day divided every 6 to 8 hours; recommended duration: 7 to 21 days (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Health care-associated pneumonia (HAP) (methicillin-resistant/clindamycin-susceptible): Children: Oral, IV: 30 to 40 mg/kg/day divided every 6 to 8 hours for 7 to 21 days (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against infective endocarditis (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 20 mg/kg 30 to 60 minutes before procedure (Wilson 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 20 mg/kg 30 to 60 minutes before procedure. Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications (Wilson 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic arthritis due to MRSA (off-label use):</b> IV, Oral: 10 to 13 mg/kg/dose every 6 to 8 hours for minimum of 3 to 4 weeks (maximum: 40 mg/kg/day) (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections due to MSSA:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 25 to 30 mg/kg/day divided every 8 hours for 7 to 14 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 25 to 40 mg/kg/day divided every 8 hours for 7 to 14 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections due to MRSA (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 30 to 40 mg/kg/day divided every 8 hours for 7 to 14 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 25 to 40 mg/kg/day divided every 8 hours for 7 to 14 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Complicated infections:</i> Oral, IV: 10 to 13 mg/kg/dose every 6 to 8 hours for 7 to 14 days (maximum: 40 mg/kg/day) (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cellulitis:</i> Oral: 10 to 13 mg/kg/dose every 6 to 8 hours for 5 to 10 days (maximum: 40 mg/kg/day) (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b> IV: 10 to 13 mg/kg/dose every 8 hours, in combination with cefotaxime for empiric therapy of polymicrobial infections <b>or</b> in combination with penicillin IV for the treatment of group A streptococcal or <i>Clostridium</i> species necrotizing infections. May give as monotherapy for MSSA. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Streptococcal skin infections:</b> IV: 10 to 13 mg/kg/dose every 8 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis (off-label use):</b> IV: 10 mg/kg within  60 minutes prior to surgical incision. Doses may be repeated in 6 hours if procedure is lengthy (maximum single dose: 900 mg) (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Toxoplasma gondii</i></b> <b>encephalitis in HIV-exposed/-positive patients (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i> IV, Oral: 5 to 7.5 mg/kg/dose (maximum dose: 600 mg) every 6 hours (plus pyrimethamine and leucovorin) (HHS [pediatric] 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Secondary prevention: </i>Oral: 7 to 10 mg/kg/dose (maximum dose: 600 mg) every 8 hours (plus pyrimethamine and leucovorin) (HHS [pediatric] 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008118\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008119\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to severe impairment: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease (ESRD) on hemodialysis or peritoneal dialysis: Not removed from serum (eg, poorly dialyzed); no supplemental dose or dosage adjustment necessary (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous renal replacement therapy (CRRT) (eg, CVVH, CVVHD, CVVHDF): No supplemental dose or dosage adjustment necessary (Heintz 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008120\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling; in studies of patients with moderate or severe liver disease, half-life is prolonged, however, when administered on an every 8 hour schedule, accumulation should rarely occur. In severe liver disease, use caution and monitor liver enzymes periodically during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008168\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin: 75 mg, 150 mg [contains brilliant blue fcf (fd&amp;c blue #1), tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin: 300 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg, 150 mg, 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as phosphate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CLIN Single Use: 300 mg/2 mL [contains benzyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as phosphate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin Phosphate: 300 mg/2 mL (2 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin Phosphate: 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL) [contains benzyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin Phosphate: 900 mg/6 mL (6 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin Phosphate: 900 mg/6 mL (6 mL); 9 g/60 mL (60 mL) [contains benzyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL); 9000 mg/60 mL (60 mL); 9 g/60 mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as phosphate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin in D5W: 300 mg/50 mL (50 mL); 600 mg/50 mL (50 mL); 900 mg/50 mL (50 mL) [contains edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin Phosphate: 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL) [contains benzyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/50 mL (50 mL); 600 mg/50 mL (50 mL); 900 mg/50 mL (50 mL); 150 mg/mL (2 mL); 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL); 300 mg/50 mL in NaCl 0.9% (50 mL); 600 mg/50 mL in NaCl 0.9% (50 mL); 900 mg/50 mL in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Oral, as palmitate hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin: 75 mg/5 mL (100 mL) [contains ethylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg/5 mL (100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008035\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50338192\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule, Oral, as hydrochloride [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dalacin C: 150 mg, 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution, Intravenous, as phosphate [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dalacin C Phosphate: 150 mg/mL (2 mL, 4 mL, 6 mL, 60 mL) [contains benzyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution Reconstituted, Oral, as palmitate hydrochloride [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dalacin C Flavoured Granules: 75 mg/5 mL (100 mL) [contains ethylparaben]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008139\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Deep IM sites, rotate sites; do not exceed 600 mg in a single injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: <b>Never administer undiluted as bolus</b>; administer by IV intermittent infusion over at least 10 to 60 minutes, at a maximum rate of 30 mg/minute (do not exceed 1,200 mg/hour).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Capsule should be taken with a full glass of water to avoid esophageal irritation; shake oral solution well before use; may administer with or without meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008044\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Bone and joint infections:</b> Treatment of bone and joint infections, including acute hematogenous osteomyelitis caused by <i>Staphylococcus aureus</i> and as adjunctive therapy in the surgical treatment of chronic bone and joint infections caused by susceptible organisms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Gynecological infections: </b> Treatment of gynecologic infections, including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Intra-abdominal infections:</b> Treatment of intra-abdominal infections, including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Lower respiratory tract infections:</b> Treatment of lower respiratory tract infections, including pneumonia, empyema, and lung abscess caused by anaerobes, <i>Streptococcus pneumoniae</i>, other streptococci (except <i>Enterococcus faecalis</i>), and <i>S. aureus</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Septicemia:</b> Treatment of septicemia caused by <i>S. aureus</i>, streptococci (except <i>E. faecalis</i>), and susceptible anaerobes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Skin and skin structure infections:</b> Treatment of skin and skin structure infections caused by <i>Streptococcus pyogenes</i>, <i>S. aureus</i>, and anaerobes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475290\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute bacterial rhinosinusitis; Acute otitis media (children); Anthrax; Babesiosis; Bacterial vaginosis; Bite wounds (animal); Community-acquired pneumonia (children); Diabetic foot infections; Group A streptococcal pharyngitis (adults); Group B Streptococcus (GBS) infection (maternal use for neonatal prophylaxis in penicillin-allergic women); Infective endocarditis (prophylaxis); Malaria; Methicillin-resistant Staphylococcus aureus (MRSA) infection; Pneumocystis pneumonia (PCP) in HIV-infected patients (adolescents and adults); Prophylaxis in patients with prosthetic joint implants undergoing dental procedures which produce bacteremia; Prosthetic joint infection; Skin and soft tissue necrotizing infections; Surgical (perioperative) prophylaxis (injection); Toxoplasma gondii encephalitis (treatment/chronic maintenance) in HIV-infected patients (adolescents and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8007988\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin may be confused with bleomycin, Clinoril, Cubicin, Lincocin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clindamycin may be confused with clarithromycin, Claritin, vancomycin, lincomycin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008064\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypotension (rare; IV administration), thrombophlebitis (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Metallic taste (IV) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Acute generalized exanthematous pustulosis, erythema multiforme (rare), exfoliative dermatitis (rare), maculopapular rash, pruritus, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis, urticaria, vesiculobullous dermatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, antibiotic-associated colitis, <i>Clostridium difficile</i> associated diarrhea, diarrhea, esophageal ulcer, esophagitis, nausea, pseudomembranous colitis, unpleasant taste (IV), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Azotemia, oliguria, proteinuria, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, eosinophilia (transient), neutropenia (transient), thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal hepatic function tests, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactic shock, anaphylactoid reaction (rare), anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: DRESS syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Abscess at injection site (IM), induration at injection site (IM), irritation at injection site (IM), pain at injection site (IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Polyarthritis (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal insufficiency (rare)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008053\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to clindamycin, lincomycin, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Oral clindamycin: Infants &lt;30 days of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008062\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Colitis: <b> [US Boxed Warning]: Can cause severe and possibly fatal colitis.</b><b> Should be reserved for serious infections where less toxic antimicrobial agents are inappropriate. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. Hypertoxin-producing strains of</b> <b><i>C. difficile</i></b> <b> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. </b><b><i>C. difficile</i></b><b>-associated diarrhea (CDAD) must be considered in all patients who present with diarrhea following antibiotic use. CDAD has been observed &gt;2 months postantibiotic treatment. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against </b><b><i>C. difficile</i></b> <b> may need to be discontinued. Institute appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of </b><b><i>C. difficile</i></b><b>, and surgical evaluation as clinically indicated.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe hypersensitivity reactions, including severe skin reactions (eg, drug reaction with eosinophilia and systemic symptoms [DRESS], Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN]), some fatal, and anaphylactic reactions, including anaphylactic shock, have been reported. Permanently discontinue treatment and institute appropriate therapy if these reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Use may result in overgrowth of nonsusceptible organisms, particularly yeast. Should superinfection occur, appropriate measures should be taken as indicated by the clinical situation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disease: Use with caution in patients with a history of GI disease, particularly colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with moderate to severe liver disease, however, when administered at every-8-hour intervals, drug accumulation is rare. Monitor hepatic enzymes periodically as dosage adjustments may be necessary in patients with severe  liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atopic patients: Use with caution in atopic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: A subgroup of older patients with associated severe illness may tolerate diarrhea less well. Monitor carefully for changes in bowel frequency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tartrazine: Some products may contain tartrazine (FD&amp;C yellow no. 5), which may cause allergic reactions in certain individuals. Allergy is frequently seen in patients who also have an aspirin hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration (IV):  Do not inject IV undiluted as a bolus. Product should be diluted in compatible fluid and infused over 10 to 60 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not appropriate for use in the treatment of meningitis due to inadequate penetration into the CSF.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299057\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008069\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9064&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Clindamycin (Systemic). Refer to the specific clindamycin (systemic) - rifampin drug interaction monograph for information concerning that combination.<b> Exceptions: </b>RifAMPin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kaolin: May decrease the absorption of Lincosamide Antibiotics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008048\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Clindamycin crosses the placenta and can be detected in the cord blood and fetal tissue (Philipson 1973; Weinstein 1976). Clindamycin injection contains benzyl alcohol which may also cross the placenta. Clindamycin pharmacokinetics are not affected by pregnancy (Philipson 1976; Weinstein 1976). Clindamycin is recommended for use in pregnant women for the prophylaxis of group B streptococcal disease in newborns (alternative therapy) (ACOG 485, 2011); prophylaxis and treatment of <i>Toxoplasma gondii</i> encephalitis (alternative therapy), or <i>Pneumocystis pneumonia</i> (PCP) (alternative therapy) (HHS [OI adult 2015]); bacterial vaginosis (CDC [Workowski 2015]); anthrax (Meaney-Delman 2014); or malaria (CDC 2013). Clindamycin is also one of the antibiotics recommended for prophylactic use prior to cesarean delivery and may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis (ACOG 120, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008052\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The relative infant dose (RID) of clindamycin is 1.2% to 4.7% when calculated using the highest verifiable breast milk concentration located and compared to an infant therapeutic dose of 10 to 40 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest verifiable milk concentration (3.1 mcg/mL), the estimated daily infant dose via breast milk is 0.465 mg/kg/day. This milk concentration was obtained following maternal administration of oral clindamycin 150 mg three times daily for at least 1 week (St&eacute;en 1982). The manufacturer reports that clindamycin breast milk concentrations range from 0.7 to 3.8 mcg/mL (maternal dose, route, and duration not specified).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">One case of bloody stools in an infant occurred after a mother received clindamycin while breastfeeding; however, a causal relationship was not confirmed (Mann 1980). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Additional guidelines recommend to avoid clindamycin in breastfeeding women if possible; monitor breastfeeding infants for GI disturbances, diarrhea, and bloody stools if maternal treatment is required (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008146\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for changes in bowel frequency. Monitor for colitis and resolution of symptoms. In severe liver disease monitor liver function tests periodically; during prolonged therapy monitor CBC, liver and renal function tests periodically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008096\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversibly binds to 50S ribosomal subunits preventing peptide bond formation thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008098\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral, hydrochloride: Rapid (90%); clindamycin palmitate must be hydrolyzed in the GI tract before it is active</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributed in body fluids and tissues; no significant levels in CSF, even with inflamed meninges</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 94%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Biologically inactive clindamycin phosphate (intravenous formulation) is rapidly converted to active clindamycin. Clindamycin is metabolized predominantly by CYP3A4, with minor contribution by CYP3A5, to form clindamycin sulfoxide (major metabolite) and N-desmethylclindamycin (minor metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: ~90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: Premature: 8.7 hours; Full-term: 3.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 1 month to 1 year: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: ~2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Elderly (oral) ~4 hours (range: 3.4 to 5.1 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: Within 60 minutes; IM: 1 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~10%) and feces (3.6%) as active drug and metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008170\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Cleocin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $562.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $1,104.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $2,243.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Clindamycin HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (200): $144.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $119.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $371.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (CLIN Single Use Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/2 mL (1): $538.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cleocin in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/50 mL (50 mL): $13.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/50 mL (50 mL): $20.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/50 mL (50 mL): $25.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cleocin Phosphate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 g/60 mL (60 mL): $27.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/2 mL (2 mL): $2.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/4 mL (4 mL): $3.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/6 mL (6 mL): $5.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cleocin Phosphate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/2 mL (2 mL): $4.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/4 mL (4 mL): $5.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/6 mL (6 mL): $6.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clindamycin Phosphate in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/50 mL (50 mL): $9.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/50 mL (50 mL): $14.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/50 mL (50 mL): $18.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clindamycin Phosphate in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/50 mL 0.9% (50 mL): $8.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/50 mL 0.9% (50 mL): $12.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/50 mL 0.9% (50 mL): $15.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clindamycin Phosphate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 g/60 mL (60 mL): $20.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/2 mL (2 mL): $2.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/4 mL (4 mL): $3.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/6 mL (6 mL): $5.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clindamycin Phosphate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/2 mL (2 mL): $4.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/4 mL (4 mL): $5.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/6 mL (6 mL): $5.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cleocin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg/5 mL (100 mL): $163.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Clindamycin Palmitate HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg/5 mL (100 mL): $62.03</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961961\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acnocin (TH);</li>\n      <li>Albiotin (ID);</li>\n      <li>Aledo Gel (TW);</li>\n      <li>BB (TW);</li>\n      <li>Chinacin-T (TH);</li>\n      <li>Cleocin (BB);</li>\n      <li>Cleocin HCl (AU, PK, TW);</li>\n      <li>Cleocin T (TR, TW);</li>\n      <li>Clicin (VN);</li>\n      <li>Clidets (VE);</li>\n      <li>Climadan (ID, SG);</li>\n      <li>Climax (BD);</li>\n      <li>Clinacin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Clinbac (PH);</li>\n      <li>Clinbercin (ID);</li>\n      <li>Clincin (TW);</li>\n      <li>Clinda (DE);</li>\n      <li>Clinda-P (TH);</li>\n      <li>Clindabact (LK);</li>\n      <li>Clindac-A (IN);</li>\n      <li>Clindacid (PY);</li>\n      <li>Clindacin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PE, SA, SY, YE);</li>\n      <li>Clindagen (PH);</li>\n      <li>Clindal (PH);</li>\n      <li>Clindala (ID);</li>\n      <li>Clindalin (TH);</li>\n      <li>Clindatec (PH);</li>\n      <li>Clindavid (TH);</li>\n      <li>Clindox (JO);</li>\n      <li>Clinott (TH);</li>\n      <li>Cliz (PH);</li>\n      <li>Dacin (SG);</li>\n      <li>Daclin (BD);</li>\n      <li>Daklin (PH);</li>\n      <li>Dalacin (AE, BD, ES, HU, IE, IS, JO, QA, TH, UA);</li>\n      <li>Dalacin C (AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DK, DO, EC, EE, EG, ET, GB, GH, GM, GN, GR, GT, HK, HN, HR, ID, IE, IL, IN, IQ, IR, IT, KE, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PL, PT, QA, RO, SA, SC, SD, SG, SI, SK, SL, SN, SV, SY, TH, TN, TR, TZ, UA, UG, UY, VN, YE, ZA, ZM, ZW);</li>\n      <li>Dalacine (FR);</li>\n      <li>Dalaclin (PH);</li>\n      <li>Dalamed (PH);</li>\n      <li>Dalcap (IN);</li>\n      <li>Damicine (CO);</li>\n      <li>Damiclin V (CO);</li>\n      <li>Euroclin (EC);</li>\n      <li>Fullgram (KR);</li>\n      <li>Jutaclin (DE);</li>\n      <li>Klimicin (CZ);</li>\n      <li>Klincyn (PH);</li>\n      <li>Klinda RX (TH);</li>\n      <li>Klindamycin (TH);</li>\n      <li>Lacin (TH);</li>\n      <li>Lanacin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Lando (ID);</li>\n      <li>Librodan (ID);</li>\n      <li>Lindacin (MY, TW);</li>\n      <li>Luoqing (CN);</li>\n      <li>Neotasin (KR);</li>\n      <li>Nildacin (ID);</li>\n      <li>Peldacyn (PH);</li>\n      <li>Potecin (PH);</li>\n      <li>Qualiclinda (HK);</li>\n      <li>Queritan (PY);</li>\n      <li>Tidact (LK, PH, TW);</li>\n      <li>Todacin (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>, 16th ed, New York, NY: Medical Letter, 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ADA Division of Legal Affairs, &quot;A Legal Perspective on Antibiotic Prophylaxis,&quot; <i>J Am Dent Assoc</i>, 2003, 134(9):1260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/14529001/pubmed\" target=\"_blank\" id=\"14529001\">14529001</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2011;117(6):1472-1483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists Committee on Obstetric Practice, &quot;ACOG Committee Opinion No. 485: Prevention of Early-Onset Group B Streptococcal Disease in Newborns,&quot; <i>Obstet Gynecol</i>, 2011, 117(4):1019-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/21422882/pubmed\" target=\"_blank\" id=\"21422882\">21422882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12892448\"></a>American Dental Association, American Academy of Orthopedic Surgeons, &ldquo;Antibiotic Prophylaxis for Dental Patients With Total Joint Replacements,&rdquo; <i>J Am Dent Assoc</i>, 2003, 134(7):895-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/12892448/pubmed\" target=\"_blank\" id=\"12892448\">12892448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &quot;Combating Antibiotic Resistance,&quot; <i>J Am Dent Assoc</i>, 2004, 135(4):484-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/15127872/pubmed\" target=\"_blank\" id=\"15127872\">15127872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bader MS. Diabetic foot infection. <i>Am Fam Physician</i>. 2008;78(1):71-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/18649613/pubmed\" target=\"_blank\" id=\"18649613\">18649613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span><span class=\"doi\">10.1093/cid/civ482</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Peacock G, Krug SE, et al. Pediatric Anthrax Clinical Management. Pediatrics. 2014;133;e1411.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brook I, Frazier EH. Aerobic and anaerobic microbiology of pyomyositis. <i>Inf Dis Clin Pract</i>. 1999;8:252-256.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Diagnosis and Treatment of Malaria,&rdquo; Available at <a href=\"http://www.cdc.gov/malaria/diagnosis_treatment/index.html\" target=\"_blank\">http://www.cdc.gov/malaria/diagnosis_treatment/index.html</a>. Last accessed August 26, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Prevention of Perinatal Group B Streptococcal Disease, Revised Guidelines from CDC, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-10):1-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/21088663/pubmed\" target=\"_blank\" id=\"21088663\">21088663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Treatment of Malaria Guidelines for Clinicians 2013. Available at <a href=\"http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf%20\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cleocin Hydrochloride capsules (clindamycin) [prescribing information]. New York, NY: Pfizer; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cleocin Pediatric oral solution (clindamycin) [prescribing information]. New York, NY: Pfizer; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cleocin Phosphate Injection [prescribing information]. New York, NY: Pfizer; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dajani AS, Taubert KA, Wilson W, et al, &ldquo;Prevention of Bacterial Endocarditis. Recommendations by the American Heart Association,&rdquo; <i>JAMA</i>, 1997, 277(22):1794-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/9178793/pubmed\" target=\"_blank\" id=\"9178793\">9178793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalacin C (clindamycin) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    del Carmen Carrasco-Portugal M, Lujan M, and Flores-Murrieta FJ, &ldquo;Evaluation of Gender in the Oral Pharmacokinetics of Clindamycin in Humans,&rdquo; <i>Biopharm Drug Dispos</i>, 2008, 29(7):427-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/18623043/pubmed\" target=\"_blank\" id=\"18623043\">18623043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Parasitic Infections,&rdquo; <i>Med Lett Drugs Ther</i>, 2007, 5(suppl):e1-14.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falagas ME and Gorbach SL, &ldquo;Clindamycin and Metronidazole,&rdquo; <i>Med Clin North Am</i>, 1995, 79(4):845-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/7791427/pubmed\" target=\"_blank\" id=\"7791427\">7791427</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall G, Nord CE, and Heimdahl A, &ldquo;Elimination of Bacteraemia After Dental Extraction: Comparison of Erythromycin and Clindamycin for Prophylaxis of Infective Endocarditis,&rdquo; <i>J Antimicrob Chemother</i>, 1996, 37(4):783-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/8722544/pubmed\" target=\"_blank\" id=\"8722544\">8722544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hassell M, Fagan P, Carson P, Currie BJ. Streptococcal necrotizing fasciitis from diverse strains of <i>Streptococcus pyogenes</i> in tropical northern Australia: case series and comparison with the literature. <i>BMC Inf Dis</i>. 2004;4(1):60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/15601476/pubmed\" target=\"_blank\" id=\"15601476\">15601476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29:562-577.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span><span class=\"doi\">10.1592/phco.29.5.562</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis</i>. 2014;20(2). doi: 10.3201/eid2002.130687.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. March 1, 2016. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22527064\"></a>Hicks CW, Sweeney DA, Cui X, et al, &ldquo;An Overview of Anthrax Infection Including the Recently Identified Form of Disease in Injection Drug Users,&rdquo; <i>Intensive Care Med</i>, 2012, 38(7):1092-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22527064/pubmed\" target=\"_blank\" id=\"22527064\">22527064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jevsevar DS and Abt E, &quot;The New AAOS-ADA Clinical Practice Guideline on Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures,&quot; <i>J Am Acad Orthop Surg</i>, 2013, 21(3):195-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23457071/pubmed\" target=\"_blank\" id=\"23457071\">23457071</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katlama C, De Wit S, O'Doherty E, et al, &ldquo;Pyrimethamine-Clindamycin vs Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients With AIDS,&rdquo; <i>Clin Infect Dis</i>, 1996, 22(2):268-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/8838183/pubmed\" target=\"_blank\" id=\"8838183\">8838183</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. <i>Lancet Infect Dis</i>. 2009;9(5):281-290.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/19393958/pubmed\" target=\"_blank\" id=\"19393958\">19393958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-e999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. <i>Arch Intern Med</i>. 1990;150(4):790-797.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/2183732/pubmed\" target=\"_blank\" id=\"2183732\">2183732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children: Executive Summary,&rdquo; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luft BJ, Hafner R, Korzun AH, et al, &ldquo;Toxoplasmic Encephalitis in Patients With the Acquired Immunodeficiency Syndrome. Members of the ACTG 077p/ANRS 009 Study Team,&rdquo; <i>N Engl J Med</i>, 1993, 329(14):995-1000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/8366923/pubmed\" target=\"_blank\" id=\"8366923\">8366923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mann CF, &quot;Clindamycin and Breast-Feeding,&quot; <i>Pediatrics</i>, 1980, 66(6):1030-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/7454470/pubmed\" target=\"_blank\" id=\"7454470\">7454470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis. 2014;20(2). Available at http://dx.doi.org/10.3201/eid2002.130611</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipson A, Sabath LD, and Charles D, &quot;Erythromycin and Clindamycin Absorption and Elimination in Pregnant Women,&quot; <i>Clin Pharmacol Ther</i>, 1976, 19(1):68-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/1245094/pubmed\" target=\"_blank\" id=\"1245094\">1245094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipson A, Sabath LD, and Charles D, &quot;Transplacental Passage of Erythromycin and Clindamycin,&quot; <i>N Engl J Med</i>, 1973, 288(23):1219-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/4700555/pubmed\" target=\"_blank\" id=\"4700555\">4700555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Safrin S, Finkelstein DM, Feinberg J, et al, &ldquo;Comparison of Three Regimens for Treatment of Mild-to-Moderate <i>Pneumocystis carinii</i> Pneumonia in Patients With AIDS. A Double-Blind, Randomized, Trial of Oral Trimethoprim-Sulfamethoxazole, Dapsone-Trimethoprim, and Clindamycin-Primaquine. ACTG 108 Study Group,&rdquo; <i>Ann Intern Med</i>, 1996, 124(9):792-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/8610948/pubmed\" target=\"_blank\" id=\"8610948\">8610948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandor GK, Low DE, Judd PL, et al, &quot;Antimicrobial Treatment Options in the Management of Odontogenic Infections,&quot; <i>J Can Dent Assoc</i>, 1998, 64(7):508-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/9737082/pubmed\" target=\"_blank\" id=\"9737082\">9737082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2012, 55(10):e86-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smilack JD, Wilson WR, and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,&rdquo; <i>Mayo Clin Proc</i>, 1991, 66(12):1270-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/1749296/pubmed\" target=\"_blank\" id=\"1749296\">1749296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc.</i> 2015; 146(1):11-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/25569493/pubmed\" target=\"_blank\" id=\"25569493\">25569493</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    St&eacute;en B and Rane A, &quot;Clindamycin Passage Into Human Milk,&quot; <i>Br J Clin Pharmacol</i>, 1982, 13(5):661-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/7082533 /pubmed\" target=\"_blank\" id=\"7082533 \">7082533 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toma E, Thorne A, Singer J, et al, &ldquo;Clindamycin With Primaquine vs Trimethoprim-Sulfamethoxazole Therapy for Mild and Moderately Severe <i>Pneumocystis carinii</i> Pneumonia in Patients With AIDS: A Multicenter, Double-Blind, Randomized Trial (CTN 004). CTN-PCP Study Group,&rdquo; <i>Clin Infect Dis</i>, 1998, 27(3):524-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/9770152/pubmed\" target=\"_blank\" id=\"9770152\">9770152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated November 10, 2016. Accessed December 21, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vannier E and Krause PJ, &ldquo;Human Babesiosis,&rdquo; <i>N Engl J Med</i>, 2012, 366(25):2397-2407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22716978/pubmed\" target=\"_blank\" id=\"22716978\">22716978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinstein AJ, Gibbs RS, and Gallagher M, &quot;Placental Transfer of Clindamycin and Gentamicin in Term Pregnancy,&quot; <i>Am J Obstet Gynecol</i>, 1976, 124(7):688-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/943947/pubmed\" target=\"_blank\" id=\"943947\">943947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong CJ, Stevens DL. Serious group a streptococcal infections. <i>Med Clin North Am</i>. 2013;97(4):721-736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23809722/pubmed\" target=\"_blank\" id=\"23809722\">23809722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in<i> MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), Anthrax in Humans and Animals, 4th ed, 2008. Available at http://whqlibdoc.who.int/publications/2008/9789241547536_eng.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo; <i>J Am Geriatr Soc</i>, 1990, 38(12):1353-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/2254575/pubmed\" target=\"_blank\" id=\"2254575\">2254575</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9064 Version 264.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8007987\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8008032\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8008033\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8008037\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8008117\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8008116\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8008118\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8008119\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8008120\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8008168\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8008035\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50338192\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8008139\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8008044\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475290\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8007988\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8008064\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8008053\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8008062\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299057\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8008069\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8008048\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8008052\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8008146\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8008096\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8008098\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8008170\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961961\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9064|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clindamycin-systemic-patient-drug-information\" class=\"drug drug_patient\">Clindamycin (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=clindamycin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Clindamycin (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}